BiondVax Pharmaceuticals Ltd (BVXV)

[midastouch017]

BiondVax Announces Upcoming Expiration of Public Warrants

PR Newswire PR Newswire•May 4, 2020

JERUSALEM, May 4, 2020 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), developer of the universal influenza vaccine candidate M-001, today published a reminder that its publicly traded warrants (traded on Nasdaq under the symbol BVXVW) will expire, according to their terms, on May 15, 2020. Warrants issued to underwriters in connection with our initial public offering in the United States will expire on May 11, 2020.

As previously announced by the Company, holders of warrants may exercise their warrants on a cash or cashless exercise basis.

In order to exercise the warrants, brokers must deliver, on or before 5:00 PM (ET) on May 15, 2020 (or May 11, 2020 for holders of warrants issued to underwriters), the completed Warrant Exercise Form to the Company's transfer agent, Computershare. For warrants being exercised on a cash basis, holders must also deliver payment of the exercise price of $6.25 per ADS for the number of public warrants being exercised plus applicable issuance fees. For warrants being exercised on a cashless basis, holders must note on the Warrant Exercise Form that the warrants are being exercised on a cashless basis and deliver payment of applicable issuance fees.

For additional information and copies of the exercise forms, please contact: [e-mail]

Computershare
Voluntary Corporate Actions
150 Royall Street, Suite V
Canton, MA 02021

About BiondVax

BiondVax (NASDAQ: BVXV) is a Phase 3 clinical stage biopharmaceutical company developing a universal flu vaccine. The vaccine candidate, called M-001, is designed to provide multi-strain and multi-season protection against current and future, seasonal and pandemic influenza. BiondVax's proprietary technology utilizes a unique combination of conserved and common influenza virus peptides intended to stimulate both arms of the immune system for a cross-protecting and long-lasting effect. In a total of 7 completed Phase 1/2 and Phase 2 clinical trials enrolling 818 participants, the vaccine has been shown to be safe, well-tolerated, and immunogenic. The ongoing pivotal Phase 3 clinical trial aims to assess safety and effectiveness of M-001 in reducing flu illness and severity. For more information, please visit www.biondvax.com.

https://finance.yahoo.com/news/biondvax-announces-upcoming-expiration-public-103000796.html